PAH-HOPE SIGNED
New hope for the PAH patient: A Novel Therapeutic for Pulmonary Arterial Hypertension (PAH)
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0PAH-HOPE project word cloud
Explore the words cloud of the PAH-HOPE project. It provides you a very rough idea of what is the project "PAH-HOPE" about.
Project "PAH-HOPE" data sheet
The following table provides information about the project.
| Coordinator |
ATXA THERAPEUTICS LTD
Organization address contact info |
| Coordinator Country | Ireland [IE] |
| Project website | https://www.atxatherapeutics.com/pah-hope |
| Total cost | 3˙570˙000 € |
| EC max contribution | 2˙499˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-2 |
| Funding Scheme | SME-2 |
| Starting year | 2018 |
| Duration (year-month-day) | from 2018-10-01 to 2020-09-30 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ATXA THERAPEUTICS LTD | IE (DUBLIN) | coordinator | 2˙499˙000.00 |
Map
Project objective
ATXA Therapeutics Ltd is a company on a mission to offer new hope to patients with pulmonary arterial hypertension (PAH). PAH is a debilitating lung & heart disease with an urgent need for new medicines targeting different pathways than current drugs. These drugs do not effectively treat the disease, they carry serious side-effects, are poorly tolerated and only extend life-expectancy from 2.8 years (untreated) to 3.6 years (treated). ATXA has developed novel therapeutic drugs to treat PAH. ATXA’s drug target is the human Thromboxane Receptor, a pathway involved in all the clinical features of PAH. Based on evaluations in 2 independent animal models of PAH, ATXA’s lead NTP42 is predicted to be a truly disruptive disease-modifying drug, treating all aspects of PAH and greatly extending life expectancy. ATXA has completed the preclinical phase of its drug development program and has secured orphan designation from the EMA and FDA regulatory agencies for NTP42 for PAH treatment. The objective of PAH-HOPE is to advance ATXA’s drug NTP42 into clinical development, starting from scaled up drug manufacture through to securing regulatory clinical trial authorization (CTA). Securement of CTA will position ATXA to advance NTP42 to Phase I-III clinical trials through to marketing authorization and product launch in 2025. ATXA’s NTP42 fits with the current focus on value-based healthcare delivery, resulting in improved healthcare outcomes that matter to patients, physicians, payors but at lower cost of delivery. ATXA’s ambition is that NTP42 will capture 15% share of the lucrative PAH market resulting in $700m revenue within five years following global commercialization, growing to a mid-size SME with 155 employees. ATXA has 8 granted patents protecting NTP42 out to 2033 and beyond, which will address the imminent patent cliff of current PAH drugs. Moreover, ATXA’s NTP42 has platform applications in several other disease areas with blockbuster demand & market potential.
Publications
| year | authors and title | journal | last update |
|---|---|---|---|
| 2019 |
T Kinsella, E Mulvaney, HM Reid Efficacy of the novel thromboxane receptor antagonist NTP42 alone, or in combination with Sildenafil, in the sugen/hypoxia-induced model of pulmonary arterial hypertension published pages: , ISSN: , DOI: |
European Journal of Cardiology 40 | 2019-10-07 |
| 2019 |
T Kinsella, E Mulvaney, HM Reid NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension published pages: , ISSN: , DOI: |
European Respiratory Journal | 2019-10-07 |
| 2019 |
Eamon P. Mulvaney, Ãine G. O\'Sullivan, Sarah B. Eivers, Helen M. Reid, B. Therese Kinsella Differential expression of the TPα and TPβ isoforms of the human T Prostanoid receptor during chronic inflammation of the prostate: Role for FOXP1 in the transcriptional regulation of TPβ during monocyte-macrophage differentiation published pages: 104277, ISSN: 0014-4800, DOI: 10.1016/j.yexmp.2019.104277 |
Experimental and Molecular Pathology 110 | 2019-08-30 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PAH-HOPE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "PAH-HOPE" are provided by the European Opendata Portal: CORDIS opendata.